gms | German Medical Science

77th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

24.05. - 28.05.2006, Mannheim

Hyperfractionated accelerated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma

Meeting Abstract

  • corresponding author presenting/speaker Markus Fischer - Department of Oto-Rhino-Laryngology, Essen, Germany
  • Christoph Pöttgen - Department of Radiotherapy, Essen, Germany
  • Silke Wechsler - Department of Oto-Rhino-Laryngology, Essen, Germany
  • Martin Stuschke - Department of Radiotherapy, Essen, Germany
  • Klaus Jahnke - Department of Oto-Rhino-Laryngology, Essen, Germany

German Society of Otorhinolaryngology, Head and Neck Surgery. 77th Annual Meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery. Mannheim, 24.-28.05.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06hno066

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/hno2006/06hno066.shtml

Published: September 7, 2006

© 2006 Fischer et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: The excellent results of hyperfractionated and accelerated radiotherapy with concurrent chemotherapy in locally advanced oropharyngeal and hypopharyngeal carcinomas lead to the investigation of this therapeutic regime in nasopharyngeal carcinomas as well.

Methods: 39 patients with nasopharyngeal carcinomas in stage III and IV received accelerated hyperfractionated radiotherapy with concurrent chemotherapy (5-FU, mitomycin C and leucovorin). Primary tumour and regional lymph nodes received 5 x 2 Gy/fr/week during the first three weeks. Thereafter the treatment was accelerated with two daily fractions of 1.4 Gy to a total dose of 72 Gy.

Results: The overall response rate was 100%. The mean follow-up period was 76.2 months. In ten patients salvage surgery of the lymph nodes was performed revealing vital tumour in six cases. The 5 years-overall survival rate was 70+/-8%.

Conclusion: The hyperfractionated accelerated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinomas is effective and feasible.